David J. Bearss

David J. Bearss

Company: Halia Therapeutics, Inc

Job title: CSO & President


First-in-Class Allosteric Inhibitor of NEK7 to Block NLRP3 Inflammasome Assembly 12:00 pm

Allosteric inhibition of NEK7 stops NLRP3 complexing NLRP3 complexing can be reversed through NEK7 inhibition Further, NEK7 inhibition initiates downstream changes in inflammatory signalling & suppresses pro-inflammatory cytokine propagationRead more

day: Day 1 - Track B - Morning

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.